共查询到20条相似文献,搜索用时 62 毫秒
1.
运动性疲劳状态下大鼠骨骼肌线粒体氧化磷酸化功能的研究 总被引:6,自引:0,他引:6
目的和方法 :以SD大鼠递增负荷力竭性跑台运动为运动性疲劳模型 ,分别测定运动后即刻骨路肌线粒体 :①呼吸链复合体Ⅱ Ⅲ电子传递与质子泵出比值 (H /2e) ;②以琥珀酸 (S)为底物的呼吸控制 :态 3呼吸速率(R3 )、态 4呼及速率 (R4 )、呼吸控制比 (RCR)和磷 /氧比 (P/O) ;②H ATPase合成活力 ,探讨疲劳性运动中线粒体氧化磷酸化功能改变的机理。结果 :力竭性运动后以S为底物的线粒体R4升高 2 1.10 % (P <0 .0 5 ) ;呼吸链复合体Ⅱ Ⅲ的总、净H 2e分别降低 8.5 3和 19.5 1% (均P <0 .0 5 )。底物的RCR和P/O呈显著降低 (均P <0 .0 5 ) ,而底物的R3则有所增加 (P >0 .0 5 ) ,H ATPase合成活力降低 16.68% (P <0 .0 5 )。结论 :线粒体质子漏增加 ,呼吸链电子传递与质子泵出偶联程度下降 ,氧化磷酸化脱偶联导致无效氧耗增多 ,可能是运动性疲劳状态下线粒体氧利用率下降的重要机制。 相似文献
2.
大鼠烫伤早期(烫伤后30min),肝线粒体质子和电子传递速度均加快,线粒体能化态跨膜电位降低(均以琥珀酸为底物),线粒体膜脂流动性降低。皮下注射去甲肾上腺素后也有上述现象发生。推测急性应激通过儿茶酚胺类作用于肝细胞,导致线粒体内膜有序性增强所致。 相似文献
3.
膀胱癌是泌尿生殖系统最常见的恶性肿瘤,但其发生、发展的机制不清楚.通过采用逆转录聚合酶链反应(RT-PCR)方法检测58例膀胱癌组织、12例时照膀胱组织LOXL4(lysyl oxidase-like protein 4)mRNA的表达及其与临床分期、病理分级的关系.研究发现,58例膀胱癌组织中,LOXIA mRNA阳性表达率为24.1%(14/58),对照膀胱正常组织中LOXL4 mRNA阳性表达率为100%(12/12),膀胱癌组LOXL4 mRNA阳性表达率明显低于对照组(P<0.05).在膀胱癌组织不同临床分期中,Ta~1期阳性表达率为40%(10/25),T2~4期阳性表达率为12.1%(4/33),T2-4期膀胱癌组LOXL4 mRNA阳性表达率低于Ta~1期膀胱癌(P<0.05).不同病理分级膀胱癌组织中,G1阳性表达率为42.9%(9/21),G2~3阳性表达率为13.5%(5,37),G2~3膀胱癌组LOXIA mRNA阳性表达率低于G1膀胱癌(P<0.05).结果表明膀胱癌组LOXL4 mRNA表达水平明显低于正常对照组,LOXL4 mRNA的表达与膀胱癌的临床分期和病理分级呈负相关.提示LOXL4失表达、低表达可能是膀胱癌发生、发展的关键因素之一. 相似文献
4.
目的:探讨去窦弓神经对脑细胞线粒体氧化磷酸化功能的影响。方法:用氧电极法及华氏减压法测定线粒体的耗氧量、呼吸控制率(RCR)和二磷酸腺苷/氧比值(ADP/O)。结果:线粒体结构完整性和氧化磷酸化效率明显降低(P0.01),且随时间延长逐渐降低(P0.05或P0.01)。结论:去窦弓神经使脑细胞线粒体的结构和功能遭到一定程度的破坏,且随时间延长日益严重。 相似文献
5.
目的:探讨膀胱癌组织中趋化因子受体4(CXCR4)和趋化因子受体7(CXCR7)的表达及临床意义。方法:收集2012年1月至2014年1月我院收集的膀胱癌组织标本96例,肿瘤旁正常组织标本42例,采用免疫组化方法检测组织标本中CXCR4和CXCR7的表达情况。结果:96例癌组织中检出CXCR4阳性59例,阳性率为61.46%,检出CXCR7阳性表达71例,阳性率为73.96%;42例癌旁组织中检出CXCR4阳性11例,阳性率26.19%,检出CXCR7阳性8例,阳性率为19.05%,癌组织与癌旁组织中CXCR4和CXCR7的表达具有统计学差异(均P0.05);相关性分析显示在膀胱癌组织中,CXCR4和CXCR7的表达呈正相关性(r=0.497,P=0.001);CXCR4和CXCR7在浸润性高(T2-T3)的膀胱癌和分化程度低(G2-G3)的膀胱癌表达强度较高,且差异具有统计学意义(均P0.05)。结论:CXCR4和CXCR7协同参与了膀胱癌的发生发展,并且与肿瘤的分化程度和浸润程度密切相关,有望成为诊断和治疗的重要靶点,在临床应用上具有重要意义。 相似文献
6.
目的探讨补骨脂素对人膀胱癌T24细胞存活率、细胞周期、细胞凋亡和迁移的影响及其分子机制。 方法分别用细胞培养液、3‰二甲基亚砜(DMSO)和不同浓度(10、30、50、100 μg/mL)补骨脂素处理膀胱癌细胞分成对照组、DMSO组和补骨脂素组,CCK-8检测细胞存活率。流式细胞术检测细胞周期和细胞凋亡。划痕实验检测划痕愈合率。RT-qPCR法检测磷脂酰肌醇3激酶(PI3K)和蛋白激酶B (AKT) mRNA表达水平、Western blot法检测PI3K和AKT蛋白的表达及磷酸化情况。多组间比较采用单因素方差分析,组间两两比较采用LSD-t检验。 结果与DMSO组比较,除10 μg/mL补骨脂素作用24 h外,其余浓度补骨脂素作用不同时间的细胞存活率随着补骨脂素浓度增高、作用时间延长而逐渐降低(P < 0.05)。与DMSO组比较,30、100 μg/mL补骨脂素干预24 h后,G1期细胞比例增多,G2/M期比例减少,细胞凋亡率[(9.16±0.97)%、(15.45±1.57)%比(1.02±0.36)%]升高,划痕愈合率[24 h:(45.00±3.44)%、(27.60±2.21)%比(66.10±2.61)%,48 h:(70.00 ± 3.40)%、(45.17±2.44)%比(85.17±3.85)%]降低,PI3K、AKT mRNA表达以及PI3K、AKT蛋白表达水平和磷酸化水平均降低(P均< 0.05)。 结论补骨脂素降低膀胱癌细胞存活率、阻滞细胞周期、诱导细胞凋亡和抑制细胞迁移,其机制可能与下调PI3K、AKT mRNA、蛋白表达及磷酸化水平有关。 相似文献
7.
目的:人骨形成蛋白9(bone morphogenetic protein 9,BMP9)对人膀胱癌BIU-87细胞增殖和迁移的影响。方法:使用过表达BMP9基因的腺病毒(AdBMP9)感染BIU-87细胞,采用定量PCR检测BMP9 mRNA的表达,Western blot检测BMP9蛋白及BMP9下游相关信号通路蛋白的表达;MTT及集落形成实验检测BIU-87细胞增殖能力;划痕愈合实验及Transwell TM小室迁移实验检测BIU-87细胞迁移能力。结果:感染AdBMP9后,BIU-87细胞中BMP9的mRNA水平和蛋白质水平均显著增加;过表达BMP9后,BIU-87细胞的体外增殖和迁移能力明显增加;Western blot结果显示BMP9可明显激活AKT信号通路。结论:高表达BMP9可能通过激活AKT信号通路促进人膀胱癌BIU-87细胞的增殖和迁移。 相似文献
8.
9.
构建miRNA-29a/c的重组腺病毒并观察其对膀胱癌T24细胞增殖能力的调控。以人全基因组DNA为模板,PCR扩增miR-29a、miR-29c,克隆至腺病毒穿梭载体pAdtrace-TO4-CMV。重组穿梭载体经pme I线性化后与腺病毒骨架质粒pAdEasy-1共转化感受态大肠杆菌BJ5183,通过同源重组获得重组腺病毒质粒pAdEasy-1-miR-29a、pAdEasy-1-miR-29c,pac I线性化后转染HEK-293细胞,进行包装和扩增。实时荧光定量PCR检测感染腺病毒的膀胱癌T24细胞中miR-29a、miR-29c的表达水平,并利用CCK-8实验检测细胞增殖能力。经DNA测序和限制性内切酶分析显示,重组腺病毒质粒pAdEasy-1-miR-29a、pAdEasy-1-miR-29c构建成功;感染腺病毒Ad-miR-29a和Ad-miR-29c后,经实时荧光定量PCR检测,膀胱癌细胞中miR-29a、miR-29c表达显著增高(P0.01);过表达miR-29a/c后的CCK-8实验显示,细胞增殖能力明显低于对照组(P0.05)。以上说明已成功构建miR-29a、miR-29c腺病毒,过表达miR-29a/c可抑制膀胱癌细胞的增殖。 相似文献
10.
探讨γ-干扰素(interferon-γ,IFN-γ)对膀胱癌细胞株T24增殖影响及其分子机制.5种不同终浓度(125、250、500、1 000、2 000 U/mL)重组人细胞因子IFN-γ处理人膀胱癌T24细胞,分别在24、48、72 h采用MTT(3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)法检测T24增殖抑制率;以作用浓度为500 U/mL IFN-γ作用T24细胞,并设为实验组,未经IFN-γ处理设为对照组.流式细胞仪检测T24细胞周期各阶段变化;RT-PCR检测hepaCAM(hepatocyte cell adhesion molecule)基因表达;Western blot检测p21WAF1蛋白表达.结果表明:IFN-γ抑制T24增殖呈时间剂量依赖性(P<0.05);与对照组相比,实验组经流式细胞仪检测提示细胞G0/G1期比例增高(n=5,P<0.01);RT-PCR结果提示hepaCAM基因表达水平升高(P<0.05);Western blot结果提示p21WAF1蛋白表达水平增高,有统计学意义(P<0.01).新基因hepaCAM在IFN-γ对膀胱癌细胞株T24增殖调节中可能起作用,并可能通过上调p21WAF1蛋白表达阻滞T24细胞于G0/G1期,而抑制T24增殖. 相似文献
11.
Qiufen He Xiao He Yun Xiao Qiong Zhao Zhenzhen Ye Limei Cui Ye Chen Min-Xin Guan 《The Journal of biological chemistry》2021,297(2)
Mammalian mitochondrial tRNA (mt-tRNA) plays a central role in the synthesis of the 13 subunits of the oxidative phosphorylation complex system (OXPHOS). However, many aspects of the context-dependent expression of mt-tRNAs in mammals remain unknown. To investigate the tissue-specific effects of mt-tRNAs, we performed a comprehensive analysis of mitochondrial tRNA expression across five mice tissues (brain, heart, liver, skeletal muscle, and kidney) using Northern blot analysis. Striking differences in the tissue-specific expression of 22 mt-tRNAs were observed, in some cases differing by as much as tenfold from lowest to highest expression levels among these five tissues. Overall, the heart exhibited the highest levels of mt-tRNAs, while the liver displayed markedly lower levels. Variations in the levels of mt-tRNAs showed significant correlations with total mitochondrial DNA (mtDNA) contents in these tissues. However, there were no significant differences observed in the 2-thiouridylation levels of tRNALys, tRNAGlu, and tRNAGln among these tissues. A wide range of aminoacylation levels for 15 mt-tRNAs occurred among these five tissues, with skeletal muscle and kidneys most notably displaying the highest and lowest tRNA aminoacylation levels, respectively. Among these tissues, there was a negative correlation between variations in mt-tRNA aminoacylation levels and corresponding variations in mitochondrial tRNA synthetases (mt-aaRS) expression levels. Furthermore, the variable levels of OXPHOS subunits, as encoded by mtDNA or nuclear genes, may reflect differences in relative functional emphasis for mitochondria in each tissue. Our findings provide new insight into the mechanism of mt-tRNA tissue-specific effects on oxidative phosphorylation. 相似文献
12.
13.
Shamsi Emtenani Elliot T Martin Attila Gyoergy Julia Bicher JakobWendelin Genger Thomas Kcher Maria Akhmanova Mariana Guarda Marko Roblek Andreas Bergthaler Thomas R Hurd Prashanth Rangan Daria E Siekhaus 《The EMBO journal》2022,41(12)
Cellular metabolism must adapt to changing demands to enable homeostasis. During immune responses or cancer metastasis, cells leading migration into challenging environments require an energy boost, but what controls this capacity is unclear. Here, we study a previously uncharacterized nuclear protein, Atossa (encoded by CG9005), which supports macrophage invasion into the germband of Drosophila by controlling cellular metabolism. First, nuclear Atossa increases mRNA levels of Porthos, a DEAD‐box protein, and of two metabolic enzymes, lysine‐α‐ketoglutarate reductase (LKR/SDH) and NADPH glyoxylate reductase (GR/HPR), thus enhancing mitochondrial bioenergetics. Then Porthos supports ribosome assembly and thereby raises the translational efficiency of a subset of mRNAs, including those affecting mitochondrial functions, the electron transport chain, and metabolism. Mitochondrial respiration measurements, metabolomics, and live imaging indicate that Atossa and Porthos power up OxPhos and energy production to promote the forging of a path into tissues by leading macrophages. Since many crucial physiological responses require increases in mitochondrial energy output, this previously undescribed genetic program may modulate a wide range of cellular behaviors. 相似文献
14.
膀胱尿路上皮细胞癌(urothelial carcinoma of bladder, UCB)是泌尿系统常见的恶性肿瘤,是膀胱癌(bladder cancer, BC)最常见的病理类型。UCB具有高发病率、高死亡率和易复发等特点,对人类健康构成巨大威胁。引发UCB的原因可能与吸烟和接触有毒化学物质有关,但是随着研究的不断深入,人们发现膀胱内存在独特的微生物群,它与UCB的发生和发展密切相关。本文着重综述微生物通过尿路感染(urinary tract infection,UTI)、影响上皮-间充质转化(epithelial-mesenchymal transition, EMT)以及上调细胞程序性死亡-配体1 (programmed cell death 1ligand 1, PD-L1)的表达来参与UCB的发生和发展,同时也对健康人群与UCB患者微生物群特征以及UCB的预防和治疗等方面作了相应阐述。通过综述微生物与UCB之间的关系,为进一步明确微生物对UCB的促进作用以及研发治疗UCB的药物提供新思路。 相似文献
15.
16.
17.
Antonio J. Montero-Hidalgo Jesús M. Pérez-Gómez Antonio J. Martínez-Fuentes Enrique Gómez-Gómez Manuel D. Gahete Juan M. Jiménez-Vacas Raúl M. Luque 《Wiley interdisciplinary reviews. RNA》2023,14(3):e1760
Bladder cancer is the most common malignancy of the urinary tract worldwide. The therapeutic options to tackle this disease comprise surgery, intravesical or systemic chemotherapy, and immunotherapy. Unfortunately, a wide number of patients ultimately become resistant to these treatments and develop aggressive metastatic disease, presenting a poor prognosis. Therefore, the identification of novel therapeutic approaches to tackle this devastating pathology is urgently needed. However, a significant limitation is that the progression and drug response of bladder cancer is strongly associated with its intrinsic molecular heterogeneity. In this sense, RNA splicing is recently gaining importance as a critical hallmark of cancer since can have a significant clinical value. In fact, a profound dysregulation of the splicing process has been reported in bladder cancer, especially in the expression of certain key splicing variants and circular RNAs with a potential clinical value as diagnostic/prognostic biomarkers or therapeutic targets in this pathology. Indeed, some authors have already evidenced a profound antitumor effect by targeting some splicing factors (e.g., PTBP1), mRNA splicing variants (e.g., PKM2, HYAL4-v1), and circular RNAs (e.g., circITCH, circMYLK), which illustrates new possibilities to significantly improve the management of this pathology. This review represents the first detailed overview of the splicing process and its alterations in bladder cancer, and highlights opportunities for the development of novel diagnostic/prognostic biomarkers and their clinical potential for the treatment of this devastating cancer type. This article is categorized under:
- RNA Processing > Splicing Regulation/Alternative Splicing
- RNA in Disease and Development > RNA in Disease
18.